Steve Doberstein

Steve is an expert in protein engineering with over 20 years of experience in the design and development of antibody, cytokine, and fusion protein drugs. After receiving a PhD in Cell Biology at Johns Hopkins University School of Medicine and postdoctoral training at UC Berkeley, he held positions at successful biotech companies including Director Cell Biology at Exelixis and was VP, Research at Xencor, FivePrime Therapeutics, and Xoma. He most recently served as Chief R&D Officer at Nektar Therapeutics. Steve sits on the Board of Directors of Dicerna, and the Biotechnology Advisory Board of the University of Delaware.